Clinical trial
Study of CEP-701 in Treatment of Prostate Cancer
NCT00081601 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00081601 |
|---|---|
| Title | Study of CEP-701 in Treatment of Prostate Cancer |
| Official title | An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | CEP-701 |
| Enrollment | 30 |
| Start date | Mar 1, 2004 |
| Primary completion | May 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Apr 19, 2004 |
| Last update posted | Aug 24, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: